Comparison · NCT05093621-797f2d27
Furosemide vs Torsemide: All-cause Hospitalization
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Furosemide vs Torsemide: All-cause Hospitalization. Trial comparisons, record NCT05093621-797f2d27. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05093621-797f2d27
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.333 | 0.163 | 0.563 | wilson | |
| Risk in group 2 | 0.389 | 0.203 | 0.614 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0556 | -0.338 | 0.239 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.857 | 0.358 | 2.05 | log | |
| Odds ratio, group 1 over group 2 | 0.786 | 0.201 | 3.07 | log | |
| Number needed to treat, for one fewer participant with the outcome on Furosemide than on Torsemide | 18 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Furosemide | Furosemide, oral, dosage and frequency determined by treating physician or provider.~1 mg torsemide to 2-4 mg oral furosemide~Furosemide: Standard of care diuretic | 6 | 18 | OG000 |
| Group 2 | Torsemide | Torsemide, oral, dosage and frequency determined by treating physician or provider.~1 mg torsemide to 2-4 mg oral furosemide~Torsemide: Standard of care diuretic | 7 | 18 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- All-cause Hospitalization
- Description
- At least one hospitalization for any reason up to one year
- Time frame
- up to one year
- Population
- Data presented here is from Yale site only. Only data from the Yale site was collected and analyzed. Data from other site could not be collected.
Source ClinicalTrials.gov
Trial
- Title
- Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
- NCT number
- NCT05093621
- Phases
- PHASE3
- Conditions
- Heart Failure
- Interventions
- Furosemide, Torsemide
- Lead sponsor
- Yale University
- Results first posted
- 2024-10-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05093621?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05093621-797f2d27